Many small anti-cancer molecules targeting EGFR have been recently developed. Gefitinib (Iressa, [4-(3-chloro-4-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) -quinazoline]) is an orally active EGFR-tyrosine kinase inhibitor (EGFR-TKI) that blocks signal transduction pathways implicated in cancer cell proliferation, survival, and other host-dependent processes that promote cancer growth. Anti-tumor efficacy has been demonstrated for gefitinib in patients with relapsed or recurrent non-small cell lung cancer (NSCLC)7-9) and it is now approved for the treatment of advanced NSCLC. A recent large phase III placebo-controlled clinical study failed to demonstrate a statistically significant increase in survival using gefitinib to treat patients with advanced NSCLC refractory to prior chemotherapy (IRESSA Survival Evaluation in Lung cancer (ISEL) trial) 10). Despite these discouraging results, a remarkably rapid and often profound response to gefitinib was observed in a subgroup of 
Discussion
In this paper, non-cytotoxic doses of H2O2 and CDDP were used to elucidate the effect of ligand-independent EGFR activation on gefitinib cytotoxicity. Both H2O2 and CDDP induced EGFR autophosphorylation in a ligand-independent manner (Figs. 2, 4) and CDDP enhanced the rate of cell growth in vitro and in vivo (Figs. 1, 7) . The effect of CDDP on EGFR autophosphorylation was maintained for more than 48 h (Fig. 4) . This is a significantly greater activation period than that observed for EGFR specific ligands, which is usually less than 1 h. The activation period of autophosphorylation is significantly longer in mutant EGFR, which is hypersensitive to gefitinib, compared to wild type EGFR 12). In the present study, the activation period of EGFR autophosphorylation induced by CDDP resembled that observed for mutant EGFR activation and enhanced sensitivity to gefitinib (Figs. 5,  7) . The prolonged activation of EGFR is thought to be related to gefitinib sensitivity.
Tumor growth rate is occasionally enhanced following chemotherapy, which is thought to result from a decrease in the immune response caused by induction of myelosuppression by anti-cancer agents. In the present report, we demonstrate that non-toxic levels of CDDP enhance the growth rate of cancer cells via ligand-independent EGFR activation in vitro and in vivo (Figs. 1, 7) . These results suggest that incomplete cancer chemotherapy may enhance tumor growth due to ligand-independent EGFR activation. Ligand-independent EGFR activation is also induced by irradiation 18), alkylating agents 19), and CPT-1120). Taken together, the phenomenon of ligand-independent EGFR activation may influence tumor behavior following chemotherapy and radiotherapy and as such impact on the prognosis of cancer patients.
Evidence suggests that drugs targeting EGFR are active against NSCLC. Several clinical trials assessing the combination of gefitinib with cytotoxic agents have been evaluated in patients with NSCLC 21-23) . There is no evidence that gefitinib in combination with cytotoxic agents improves the efficacy over cytotoxic agents alone. In the clinical trial evaluating gefitinib in combination with gemcitabine and CDDP in patients with advanced NSCLC, there was no significant difference in efficacy endpoints (including overall survival, time to progression, and response rates) with or without gefitinib. While an explanation for these negative results remains an issue of debate Normanno suggested that EGFR activation by EGF enhances the sensitivity to CDDP in patients with NSCLC 24) .
Our results indicate that the ideal combination therapy may be the sequential administration of gefitinib following a platinum containing regimen, for example, or alternative administration of both treatments. The rational is that the NSCLC cells remaining after standard chemotherapy would be effectively killed by gefitinib in a combination therapy regimen.
